The pilot is a significant departure from the current model, which gives hospitals upfront discounts for some drugs.

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

Stocks capped a choppy day of trading on Wall Street with more losses Thursday after an early big tech rally faded and a ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

The suprisingly weak hiring numbers led investors to step up their expectations for an interest rate cut in September.

The Health Resources and Services Administration has opened applications for a voluntary pilot program aimed at evaluating the 340B rebate model.  The 340B Program traditionally has offered up-front ...

Mayo Clinic has treated the first person in the U.S. using a novel radioactive medicine for advanced breast cancer as part of ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

Q2 2025 Earnings Call Transcript July 31, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.46, expectations were $1.07. Operator: Good day, and welcome to the ...

World shares have retreated after President Trump issued a new set of import duties that will apply to dozens of countries as ...

Stocks capped a choppy day of trading on Wall Street with more losses Thursday after an early Big Tech rally faded and a ...